Active Biotech AB: Year-end Report January - December 2011

LUND, SWEDEN--(Marketwire - February 16, 2012) -

· Laquinimod

- a clinical trial is planned prior to filing an NDA in the US

· TASQ

- an investigator-sponsored Phase I clinical trial launched

- enrolment of patients for Phase III trial proceeding according to plan

· ANYARA

- Phase III trial continuing according to plan

· 57-57

- a clinical trial in systemic sclerosis/scleroderma initiated

· ISI

- project is proceeding as planned

· RhuDex®

- a Phase I clinical formulation study launched

· Focusing of the operation; notice of termination of employment to 25 staff members

· Net sales SEK 234.6 M (11.4)

· Operating loss SEK 100.9 M (Loss: 229.0)

· Loss after tax SEK 94,5 M (Loss: 221.1)

· Loss per share for the period was SEK 1.38 (Loss: 3.38)

Active Biotech AB (Corp. Reg. No. 556223-9227) PO Box 724, SE-220 07 Lund Tel +46 (0)46-19 20 00 Fax +46 (0)46-19 11 00 

This report is also available at www.activebiotech.com

Year-end Report January - December 2011: http://hugin.info/1002/R/1586221/497065.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Active Biotech via Thomson Reuters ONE

[HUG#1586221]